FDA Approves Foundayo (Orforglipron) — First Daily Oral GLP-1 Pill for Weight Loss

The FDA has granted approval to Eli Lilly's Foundayo, known generically as orforglipron, marking a watershed moment for patients who have been reluctant to start injectable weight-loss medications. The once-daily pill targets the same GLP-1 receptor pathway as semaglutide and tirzepatide but delivers the drug through a simple oral tablet.

Foundayo is among the first medications cleared under the FDA's new Commissioner's National Priority Voucher program, which is designed to accelerate review of treatments addressing major public health needs. In clinical trials, the pill demonstrated meaningful weight reduction, though the convenience of oral dosing is expected to dramatically expand the addressable patient population.

The approval arrives alongside oral semaglutide 25 mg, which Novo Nordisk launched in January 2026 as a pill version of Wegovy. Together, these oral options signal a shift in the GLP-1 landscape away from weekly injections and toward daily pills, potentially lowering the barrier to entry for the estimated 40 percent of eligible patients who cite needle aversion as a reason for not starting treatment.